Research programme: capsid assembly inhibitors - Arbutus Biopharma

Drug Profile

Research programme: capsid assembly inhibitors - Arbutus Biopharma

Alternative Names: ARB-168786; ARB-1820; ARB-880; Core protein inhibitors - Arbutus

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine; Enantigen Therapeutics
  • Developer Arbutus Biopharma
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 13 Jun 2018 Arbutus Biopharma plans a phase I trial for Hepatitis B in Hong Kong, Moldova, New Zealand, South Korea, Thailand in July 2018 (PO) (ACTRN12618000987268p)
  • 03 May 2018 Arbutus Biopharma plans clinical combination studies of AB 506 in Hepatitis B in 2019
  • 03 Oct 2017 Arbutus BioPharma intends to file an IND application/CTA or equivalent for AB 506 in Hepatitis B (PO) around mid-2018 to enable phase I study start
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top